Search Medical Condition
Please enter condition
Please choose location from dropdown

Fallopian Tube Cancer Clinical Trials

A listing of Fallopian Tube Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (124) clinical trials

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

OBJECTIVES: - Determine the percentage of patients with relapsed advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma who have a log linear rise in CA 125 levels. - Determine whether the log linear part of the curve is consistent enough to allow comparison of the slope before and ...

Phase

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial Fallopian Tube or Peritoneal Cancer

OBJECTIVES: - Compare the time to progressive disease in patients with recurrent ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer treated with carboplatin and ifosfamide with or without whole body hyperthermia. - Compare the response rate, duration of response, and survival time of patients treated with these regimens. - Compare ...

Phase

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

Carboplatin and Paclitaxel With or Without Cediranib in Treating Women With Relapsed Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer

OBJECTIVES: Primary - To determine the safety of adding cediranib once daily to standard platinum-based chemotherapy (arm A vs arms B plus C). - To investigate whether a minimal level of activity of cediranib can be detected by comparing progression-free survival (PFS) in patients receiving chemotherapy alone (arm A) with ...

Phase

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cavity Cancer

OBJECTIVES: Primary - Determine the safety and tolerability of combination therapy comprising phenoxodiol and docetaxel in patients with recurrent or persistent advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Secondary - Determine the effect of phenoxodiol on the toxicity of docetaxel using a weekly treatment regimen. - Determine ...

Phase

Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer

OBJECTIVES: Primary - Measure quality of life (QLQ-C30) at week 18 in patients with metastatic gynecological cancer receiving systematic nutritional supplements during first-line chemotherapy. Secondary - Study the maintenance or improvement of intake and nutritional status. - Study the quality of life during chemotherapy. - Evaluate tolerance and compliance to ...

Phase

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Study Groups: This study has 2 parts: a safety lead-in and Phase 2. If you are found to be eligible to take part in this study, you will be assigned to either the Safety Lead-in or the Phase 2 portion, depending on when you join the study. Up to 12 ...

Phase

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Epithelial gynecologic malignancies are tumors of mllerian origin, which include ovarian, endometrial, fallopian tube, and primary peritoneal cancers, and account for >70,000 new diagnoses and >22,000 deaths per year in the United States alone. Treatment typically consists of a thorough cytoreductive and staging surgery in combination with platinum/taxane chemotherapy. Newer ...

Phase N/A

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian cancer (OC) remains the most lethal gynecologic malignancy owing to late detection, intrinsic and acquired chemo-resistance and remarkable heterogeneity. There is an unmet medical need to develop new therapy modalities. In preclinical studies, GL-ONC1, has shown the ability to preferentially locate, colonize and destroy tumor cells in more than ...

Phase

Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer

The Phase 1b component is a multicenter, non-randomized, open label, uncontrolled, safety and effectiveness study to identify the recommended Phase 2 dose (R2PD) of epacadostat in combination with DPX-Survivac and cyclophosphamide. The Phase 2 component is a multicenter, randomized, open-label study to evaluate the safety and effectiveness of DPX-Survivac + ...

Phase